Opinion|Videos|March 10, 2025
Key Adverse Effects With Bladder Cancer Treatment
The Oncology Brothers, discuss how bladder cancer treatments commonly cause adverse effects, including frequent urination, painful urination, blood in urine, fatigue, nausea, hair loss, decreased immunity, diarrhea, skin irritation, and bladder inflammation. More severe effects may include organ damage, sexual dysfunction, and reduced fertility.
Advertisement
Advertisement
Related to this article
Data from the phase 3 LITESPARK-011 trial support the FDA approval of belzutifan plus lenvatinib for adults with advanced clear cell renal cell carcinoma.
In the phase 1b portion of the MELT-MM trial, elranatamab plus mezigdomide produced a 100% overall response rate in relapsed/refractory multiple myeloma.
Xiuning Le, MD, PhD, discusses the confirmatory SOHO-02 trial needed to convert sevabertinib’s accelerated approval to full approval.
A pooled analysis of the AMY2009 and AMY3001 trials showed daratumumab plus VCd yielded hematologic complete responses in cardiac-involved AL amyloidosis.
Health Canada approved epcoritamab plus lenalidomide and rituximab for relapsed/refractory grade 1 to 3a follicular lymphoma, backed by the EPCORE FL-1 trial.
David R. Gandara, MD, discusses how EMPOWER-Lung 1’s findings in KRAS G12C-mutated disease should inform the design of combination trials.
Meletios A. Dimopoulos, MD, explored how anselamimab’s benefit in kappa light chain amyloidosis fits into the evolving role of anti-fibril therapy.
The panel discussed the risk-benefit profile of the Galleri multicancer early detection test, which was evaluated in the NHS-Galleri and PATHFINDER 2 studies.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA MCGP Panel Votes in Favor of the Galleri Multicancer Early Detection Test
2
Approaching Cardiovascular Risk in Prostate Cancer Hormonal Therapy
3
FDA Grants Approval to Lirafugratinib for Advanced Cholangiocarcinoma with FGFR2 Alteration
4
Emerging Endocrine Doublets and Serial ESR1 Testing in HR+/HER2− mBC
5